Table 4 Patient demographic and summary of results for Phase Ib

Phase 1b: Accelerated Titration	DOSING	Subject/Dose	Age at Dx	Race	ECOG	C1D1	C1D8	C2D1	C2D8	C3D1	C3D8	Target Response	Overall Response	Total Exosomes received (mg)	AEs	Dx -> Dt (years)
	Dose 4: 1.2 mg	S1D4	60–69	Asian	ECOG 0	✓	✓	✓	✓	x	x	PD	PD	4.8	No related AEs	1
	Dose 5: 2.4 mg	S1D5	70–79	Caucasian	ECOG 1	✓	✓	✓	✓	✓	✓	PD	PD, NL	14.4	No related AEs	2
	Dose 6: 4.8 mg	S1D6	40–49	Caucasian	ECOG 1	✓	✓	✓	✓	✓	✓	PD	PD	28.8	No related AEs	2

Patient demographic, treatment cycle completion, response rate, total iExoKras^G12D received (expressed as the cumulative sum of exosomal proteins), and adverse events (AEs). Dosing cycles with check marks: dosing completed. Dosing cycles with ‘x’: no treatment. C1D1 Cycle 1 Day1, C1D8 Cycle 1 Day 8, etc. SD stable disease, PD progressive disease, NL new lesion, Dx -> Dt time in year from diagnosis (Dx) to cancer related death (Dt).

Quick links

Search